CTOs on the Move

ZIVO Bioscience

www.zivobioscience.com

 
ZIVO Bioscience is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on the general benefits of autoimmune and inflammatory response modulation.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
David Lafond
Vice-President of Innovation and Technology Profile

Similar Companies

EcoArray

EcoArray is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avalyn Pharma

Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.

Ankyra Therapeutics

Ankyra is developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response.

Medcura Incorporated

Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura`s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.

Cardiff Oncology

Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.